Search Site

Thomas H. Brannagan III, MD

  • Professor of Neurology at CUMC
  • Director, Peripheral Neuropathy Center
  • Director, Columbia Neuropathy Research Center
  • Co-director, Electromyography (EMG) Laboratory
Thomas H. Brannagan III, MD

Dr. Brannagan is the director of the Peripheral Neuropathy Center at Columbia University Medical Center. He graduated from the University of Virginia and also received his medical degree from the University of Virginia in Charlottesville. He completed his Neurology residency training at the Neurological Institute of Columbia Presbyterian Medical Center between 1991 and 1994. He subsequently did a Neuromuscular EMG fellowship at Columbia, followed by a Neuroimmunology fellowship in the laboratory of Dr. Norman Latov. Prior to returning to Columbia, Dr. Brannagan was the director of the Diabetic Neuropathy Research center at Cornell University in New York City and was co-director of the EMG laboratory at MCP-Hahnemann University in Philadelphia.

He is a member of the American Academy of Neurology, the American Neurological Association, as well as the American Association of Electrodiagnostic Medicine. He is also a member of the Neuropathy Association and the Peripheral Nerve Society. 

Dr. Brannagan's major interest is in the evaluation and treatment of peripheral neuropathy, particularly immune-mediated neuropathies and idiopathic neuropathies. His publications have focused on new treatments for chronic demyelinating polyneuropathy (CIDP), painful neuropathies, neuropathy associated with celiac disease and the use of IVIg in Neurological disorders. He has participated in numerous clinical trials of new agents to treat patients with peripheral neuropathy.

Departmental Appointments

  • Department of Neurology
    Division of Neuromuscular Medicine

Board Certifications

  • Neuromuscular Medicine
  • Clinical Neurophysiology
  • Neurology

Areas of Expertise

  • Amyloidosis
  • Peripheral Neuropathy
  • Neuropathy
  • Electromyography (EMG)

Education & Training

  • University of Virginia School of Medicine
  • Internship: Beth Israel Medical Center
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

Locations

  • Neurological Institute of New York

    710 West 168th Street
    Floor: 2
    New York, NY 10032
    Phone:
    (212) 305-0405
    For new and current patient appointments, call:
    (212) 305-0405
    Fax:
    (212) 305-5396

Centers/Institutes/Programs

  • EMG Laboratory
  • Neuropathy Center (Peripheral and Autonomic)

Provider Affiliations

  • NewYork-Presbyterian/Columbia

Insurance Programs

Please contact the provider's office directly to verify that your particular insurance is accepted.

  • Aetna [EPO, HMO, Medicare Managed Care, NY Signature, POS, PPO, Signature Administrators, Student Health]
  • Cigna [EPO, Great West, HMO, POS, PPO]
  • Empire Blue Cross Blue Shield [Blue Priority, EPO, HMO, Medicare (Mediblue), NYP Employee Plan, Pathway (Exchange), POS, PPO]
  • Local 1199 [Local 1199]
  • MagnaCare [MagnaCare]
  • Oxford Health Plans [Freedom, Liberty, Medicare Managed Care]
  • POMCO [POMCO]
  • UnitedHealthcare [Columbia University Employee Plan, EPO, Essential Plan, HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]

This provider accepts new patients

Appointment Phone Number: (212) 305-0405

NIH Grants

  • INTERNATIONAL, MULTI-CENTER, DOUBLE BLIND 9-MONTH FOLLOW-UP EXTENSION STUDY ASSESSING THE LONG TERM SAFETY AND TOLERABILITY OF PXT3003 IN PATIENTS WITH CHARCOT-MARIE-TOOTH DISEASE TYPE 1A. (P&S Industry Clinical Trial)

    Aug 31 2017 - Aug 31 2022

    EXPANDED ACCESS PROTOCOL OF PATISIRAN FOR PATIENTS WITH HEREDITARY TRANSTHYRETIN MEDIATED AMYLOIDOSIS (HATTR AMYLOIDOSIS) WITH POLYNEUROPATHY (P&S Industry Clinical Trial)

    Apr 4 2017 - Apr 4 2022

    AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF ISIS 420915 IN PATIENTS WITH FAMILIAL AMYLOID POLYNEUROPATHY (FAP) (P&S Industry Clinical Trial)

    Jul 18 2014 - Jul 18 2019

    PERIPHERAL NERVE DISORDERS FELLOWSHIP (Private)

    Jul 1 2016 - Jun 30 2019

    APOLLO: A PHASE 3 MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALN-TTR02 IN TRANSTHYRETIN (TTR)-MEDIATED POLYNEUROPATHY (FAMILIAL AMYLOIDOTIC POLYNEUROPATHY-FAP) (P&S Industry Clinical Trial)

    Dec 20 2013 - Dec 20 2018

    A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CBX129801 (ERSATTA?), LONG-ACTING SYNTHETIC C-PEPTIDE, IN TYPE 1 DIABETES MELLITUS SUBJECTS WITH MILD TO MODERATE DIABETIC PERIPHERAL NEUROPATHY (P&S Industry Clinical Trial)

    Jul 2 2013 - Jul 2 2018

    A PHASE 2/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ISIS 420915 IN PATIENTS WITH FAMILIAL AMYLOID POLYNUROPATHY (P&S Industry Clinical Trial)

    Apr 18 2013 - Apr 18 2018

    A DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PLACEBOCONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFELY OF FINGOLIMOD 0.5 MG ADMINISTERED ORALLY ONCE DAILY VERSUS PLACEBO IN PATIENTS WITH CIDP (P&S Industry Clinical Trial)

    Feb 20 2013 - Feb 20 2018

    PATIENT ASSISTED INTERVENTION FOR NEUROPATHY: COMPARISON OF TREATMENT IN REAL LIFE SITUATIONS (PAIN-CONTROLS) (Private)

    Jul 1 2014 - Mar 31 2017

    INTERNATIONAL GUILLAIN-BARRE SYNDROME OUTCOMES STUDY (IGOS) (Private)

    Oct 25 2013 - Oct 24 2016

    CLINICAL AND TRANSLATIONAL SCIENCE AWARD (Federal Gov)

    Sep 30 2006 - Jun 30 2016

    LMS-002 (P&S Industry Clinical Trial)

    Jun 17 2011 - Jun 17 2016

    A PLACEBO CONTROLLED, RANDOMIZED, DOUBLE BLIND TRIAL OF MILNACIPRAN FOR THE TREATMENT OF IDIOPATHIC NEUROPATHIC PAIN (P&S Industry Clinical Trial)

    Dec 5 2010 - Dec 8 2015

    SB-509-901 (P&S Industry Clinical Trial)

    Jun 30 2010 - Jun 30 2015

    PERIPHERAL NEUROPATHY FELLOWSHIP (Private)

    Jul 1 2011 - Jun 30 2014